Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have received a consensus rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.70.
Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Ocular Therapeutix in a research note on Friday, March 9th. BTIG Research reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research note on Sunday, March 11th. ValuEngine raised shares of Ocular Therapeutix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Tuesday, March 13th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, March 8th.
Shares of NASDAQ:OCUL opened at $6.48 on Friday. The firm has a market cap of $242.31, a price-to-earnings ratio of -2.95 and a beta of 1.25. Ocular Therapeutix has a 12-month low of $3.30 and a 12-month high of $11.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.23 and a quick ratio of 3.22.
Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.14. Ocular Therapeutix had a negative net margin of 3,296.20% and a negative return on equity of 145.73%. The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.51 million. During the same quarter last year, the business posted ($0.52) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts forecast that Ocular Therapeutix will post -1.91 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its stake in shares of Ocular Therapeutix by 1.0% in the 4th quarter. Jennison Associates LLC now owns 1,994,768 shares of the biopharmaceutical company’s stock valued at $8,877,000 after purchasing an additional 20,132 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Ocular Therapeutix by 0.8% in the 4th quarter. BlackRock Inc. now owns 1,418,577 shares of the biopharmaceutical company’s stock valued at $6,312,000 after purchasing an additional 11,293 shares during the last quarter. Hikari Power Ltd acquired a new stake in shares of Ocular Therapeutix in the 4th quarter valued at $356,000. Virtu Financial LLC acquired a new position in Ocular Therapeutix during the 4th quarter worth $280,000. Finally, Deutsche Bank AG lifted its position in Ocular Therapeutix by 148.7% during the 4th quarter. Deutsche Bank AG now owns 50,065 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 29,938 shares during the last quarter. 36.24% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/15/ocular-therapeutix-inc-ocul-given-consensus-recommendation-of-buy-by-brokerages.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.